Notice: This company recently went public with an IPO on Friday, February 14th 2025. They issued 5,900,000 shares at $16.00-$18.00 per share. We will continue to update data for AARD as it becomes available. Aardvark Therapeutics (AARD) Competitors $14.02 -3.23 (-18.72%) As of 02/21/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends AARD vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Aardvark Therapeutics (NASDAQ:AARD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Is ATNFW or AARD more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Aardvark Therapeutics N/A N/A N/A Does the MarketBeat Community favor ATNFW or AARD? 180 Life Sciences and Aardvark Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AAardvark TherapeuticsN/AN/A Which has better valuation & earnings, ATNFW or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AAardvark TherapeuticsN/AN/AN/AN/AN/A Does the media favor ATNFW or AARD? In the previous week, Aardvark Therapeutics had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 3 mentions for Aardvark Therapeutics and 1 mentions for 180 Life Sciences. Aardvark Therapeutics' average media sentiment score of 1.66 beat 180 Life Sciences' score of 1.38 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAardvark Therapeutics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark Therapeutics IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.17B$5.85B$9.15BDividend YieldN/A13.55%4.76%3.85%P/E RatioN/A9.5716.5114.19Price / SalesN/A2,330,818.99450.0276.60Price / CashN/A16.7738.0134.95Price / BookN/A3.167.644.63Net IncomeN/A$83.86M$3.18B$245.69M7 Day Performance5.41%-0.65%-1.95%-2.68%1 Month PerformanceN/A5.94%-0.23%-2.16%1 Year PerformanceN/A8.95%16.69%12.90% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$14.02-18.7%N/AN/A$0.00N/A0.0018Insider TradeNews CoveragePositive NewsGap UpATNFW180 Life SciencesN/A$0.01+1.0%N/A+51.5%$0.00N/A0.007News CoveragePositive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.03-9.0%N/A-13.4%$0.00N/A0.002Gap DownHigh Trading VolumeAIMDWAinosN/A$0.11-5.3%N/A+138.5%$0.00$40,633.000.0040Gap DownALVOWAlvotechN/A$2.25+1.8%N/A-46.2%$0.00$391.87M0.004Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05flatN/A-54.4%$0.00N/A0.004BFRIWBiofronteraN/A$0.06flatN/A+254.1%$0.00$35.36M0.0070BTMDWbioteN/A$0.50flatN/A-46.2%$0.00$193.06M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.12-7.6%N/A-92.9%$0.00N/A0.008Gap DownCELUWCelularityN/A$0.07+2.9%N/A+120.8%$0.00$48.20M0.00220Gap Up Related Companies and Tools Related Companies ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives ACABW Alternatives BFRIW Alternatives BTMDW Alternatives BCTXW Alternatives CELUW Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AARD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredThis quote from Elon says it all… (AI Breakthrough)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AARD Stock Alerts